Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

A Hard Year For Software IPOs

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: A Hard Year For Software IPOs Date: 2026-09-16 11:00 Source: https://news.crunchbase.com/public/energy-ai-defense-saas-ipos-2026/ <p>If you’re looking to measure tech IPO market strength by the amount of money companies have raised, 2026 is certainly up there.</p> <p>U.S…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The paucity of enterprise software IPOs this year is not entirely surprising given the impact of AI on the sector, as VCs pour capital into newer AI-first platforms and existing SaaS unicorns rush to incorporate AI

    60% confidence

  • Investment returns in tech IPOs are more concentrated than ever, with a winner-take-almost-all tilt in IPO proceeds more pronounced than in the past

    60% confidence

  • U.S. venture-backed technology companies have secured nearly $90 billion in domestic public offerings this year, the second-highest annual tally on record, with a few months still to go

    60% confidence

Data points we hold from this source

SpaceX · ipo proceeds share83 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
A Hard Year For Software IPOs — Source | Via News | Via News